Assess recent clinical trial evidence showing a shift toward convenient oral diabetes therapies and notable weight-loss outcomes.
Key Takeaways
- Elecoglipron is an oral small-molecule GLP-1 receptor agonist tested in adults with diabetes
- Multicentre phase 2b randomized placebo-controlled trial showed improved glycemic control versus placebo
- Participants also experienced substantial weight loss during the trial compared with placebo